Publication: 2082

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild type stage III colon cancers from an adjuvant chemotherapy trial (N0147 Alliance)
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 20 (11) 3033-3043
Year:
2014
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
3
Parents:
984  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, K05CA-142885, U10 CA031946, U10 CA033601, U10 CA037404, U10 CA180821, U24 CA114740, CA-114740, CA-25224, U10 CA180790, P30 CA015083, P30 CA016058, K05 CA142885, U10 CA025224, CA31946, CA37404  
Corr. Author:
 
Authors:
                       
Networks:
 
Study
NCCTG-N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
KRAS, colon cancer, prognosis, BRAF, survival